Plaisance Capital’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Plaisance Capital’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-9,620	Closed	-$640K	–	39
2020 Q2	$640K	Sell	9,620 -2,000	-17%	-$134K	0.68%	24
2020 Q1	$711K	Buy	+11,620	New	+$861K	0.57%	37

Other funds holding TARO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Plaisance Capital's TARO Position: Q3 2020 in Review

Plaisance Capital sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q3 2020, closing a stake of 9,620 shares — an estimated $640K sold.

Plaisance Capital first reported a position in TARO in Q1 2020 and held it in 2 quarters. The position peaked at $711K in Q1 2020. 78 funds tracked by Wall St. Rank hold TARO as of Q3 2020.

Plaisance Capital reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q3 2020 after selling out during the quarter.
Plaisance Capital sold 9,620 Taro Pharmaceutical Industries Ltd. shares in Q3 2020, an estimated $640K.
Plaisance Capital first reported a position in Taro Pharmaceutical Industries Ltd. in Q1 2020 and held it in 2 quarters.
Plaisance Capital's Taro Pharmaceutical Industries Ltd. position peaked at $711K in Q1 2020.
78 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q3 2020.

Based on Plaisance Capital's 13F filing for Q3 2020, filed 16 Nov 2020.